Introduction: Photobiomodulation (PBM) represents a potential treatment for non-exudative age-related macular degeneration (AMD). PBM uses wavelengths of light to target components of the mitochondrial respiratory chain to improve cellular bioenergetic outputs. The aim of this study was to further investigate the effects of PBM on clinical, quality of life (QoL) and anatomical outcomes in subjects with intermediate stage non-exudative AMD. Leia mais

Introduction: Dry age related macular degeneration (AMD) is a prevalent retinal disease that demonstrates underlying mitochondrial dysfunction contributing to disease pathology. Photobiomodulation (PBM) technology utilizes wavelengths in the 500-1000nm range to induce cellular effects resulting in improved bioenergetics and mitochondrial output. Studies suggest the benefit of PBM in subjects with Dry AMD (Markowitzetal., Retina, 2020; Merryetal., ActaOphthalmol, 2017) on clinical and anatomical outcomes. LIGHTSITEIII, a randomized, double-masked, multi-center clinical trial, follows promising data from the LIGHTSITEI, LIGHTSITEII and ELECTROLIGHT studies evaluating the multi wavelength LumiThera Valeda® Light Delivery System in dry AMD. Leia mais

Purpose: The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. Methods: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3–4 weeks) over 1 year. Outcome measures included best-corrected visual… Leia mais

Doctors and patients have found this new mode of therapy beneficial. By Hakan Kaymak, MD; and Hartmut Schwahn, PhD The development of innovative treatments for debilitating diseases such as age-related macular degeneration (AMD) is crucial to advance patient care and to reduce burdens on patients, caregivers, and physicians. The dry, or nonexudative, form of AMD… Leia mais

Abstract The purpose of this protocol proposal is to suggest a new non-invasive combined therapeutic approach for dry age-related macular degeneration (AMD), an eye disease with no approved treatment or cure. A nutraceutical approach involving dietary supplementation of antioxidants can reduce its risk. Also, photobiomodulation (PBM, or LLLT) has shown promising results with the advantage… Leia mais

A pilot clinical study lead by LumiThera founders from The Toronto and Oak Ridge Study of Photobiomodulation (TORPA) looked at the effect of photobiomodulation (PBM) in the treatment of dry AMD. The TORPA data for dry AMD patient’s showed clinically and statistically significant improvement in both visual acuity and contrast sensitivity. TORPA Clinical Study The…

Acesse: TORPA I

Acesse: TORPA II

Non-invasive photobiomodulation may help dry age-related macular degeneration by causing regression of drusen and improving retinal function with benefits in visual acuity and contrast sensitivity. By Lynda Charters; Reviewed by Graham Merry, MBBS, and Marion R. Munk, MD, PhD Photobiomodulation (PBM) may be a new non-invasive, light-based treatment for patients with dry age-related macular degeneration… Leia mais

Clark E. Tedford,¹ Scott DeLapp,¹ Steven Jacques,² and Juanita Anders³ ¹LumiThera, Inc., Poulsbo, Washington 98370 ²Oregon Health and Science University, Portland, Oregon ³Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 Background and Objective: Photobiomodulation (PBM) also known as low-level light therapy has been used successfully for the… Leia mais

Passarella S, Karu T. Institute of Laser and Information Technologies of the Russian Academy of Sciences, 142190 Troitsk, Moscow Region, Russian Federation. Abstract In addition to the major functions performed by in the cell, mitochondria play a major role in cell-light interaction. Accordingly it is generally accepted that mitochondria are crucial in cell photobiomodulation; however… Leia mais

Begum R, Powner MB, Hudson N, Hogg C, Jeffery G Institute of Ophthalmology, University College London, London, United Kingdom. Abstract Inflammation is an umbrella feature of ageing. It is present in the aged retina and many retinal diseases including age-related macular degeneration (AMD). In ageing and in AMD mitochondrial function declines. In normal ageing this… Leia mais

Gkotsi D, Begum R, Salt T, Lascaratos G, Hogg C, Chau KY, Schapira AH, Jeffery G. Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK. Moorfields Eye Hospital, UK. Institute of Neurology, University College London, UK. Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK. Abstract Progressive… Leia mais

Ivandic BT, Ivandic T. University of Heidelberg , Otto Meyerhof Centre, Heidelberg, Germany OBJECTIVE: This case report describes the effects of low-level laser therapy (LLLT) in a single patient with retinitis pigmentosa (RP). Background data: RP is a heritable disorder of the retina, which eventually leads to blindness. No therapy is currently available. METHODS: LLLT… Leia mais